Doctrine page

Antibody Claims

Are monoclonal antibody claims excluded under section 3(c), or is the real challenge novelty?

A monoclonal antibody not isolated from a human being but engineered is not excluded under section 3(c), the real challenge being establishing novelty, technical advance and not patent eligibility.

Doctrine last updated on 12 November 2026

Cite this page

Antibody Claims, Ali on Patents, www.aop.onl/antibody-claims

1In Immunas Pharma v Assistant Controller of Patents and Designs (2024) the Madras High Court held that “The real challenge with regard to a patent application in respect of a synthesized non-living substance, especially a monoclonal antibody, is establishing novelty, technical advance and not patent eligibility. For such purpose, the sequence of the antibody, especially the CDRs, may need to be compared with known antibody sequences. The patent applicant may also be required to establish that it does not fall within other exclusions in Section 3, such as sub-section (d) thereof, and further satisfy the requirements of Section 2(1)(j) of the Patents Act.” (para 19) It said that “The judgments of the IPAB, such as Biogaia, The University of British Columbia and Health Protection Agency record substantially similar conclusions.” (para 19)

Definition of Antibody

2In Immunas Pharma the Court described the antibody as “The amino acids constituting the tips of the variable regions form loops while folding, which are referred to as complementarity determining regions (CDRs). The claim of inventiveness generally centres around the sequences relating to the CDRs.” (para 10) On the claimed antibody, the Court said that “The appellant does not, however, assert inventiveness in the use of hybridoma technology. Inventiveness is asserted with regard to the production of a monoclonal antibody, which targets a specific epitope.” It held that “the antibody of the claimed invention was undoubtedly not isolated from a human being, but was engineered in the manner described in internal page 16 of the complete specification” (para 21). It found that “the antibody was generated by injecting an engineered antigen into the mice” and concluded “that the claimed invention is not excluded from patent protection under clause (c) of section 3” (para 24).

3By way of obiter, the Court in Immunas Pharma added, “Although not a concern in this case because of the nature of claims, the other legitimate concern from the Indian Patent Office perspective, in the context of monoclonal antibodies, could be to closely examine the width of claims so as to ensure that very broad claims focused entirely or largely on functionality are not allowed because that could impede instead of fostering inventiveness in future.” (para 19)

4In Genmab v Assistant Controller of Patents and Designs (2024), claim 1 was to “An antibody binding to human CD38 comprising human light chain and human heavy chain regions, wherein the light chain variable region comprises a VL CDR1 having the sequence as set forth in SEQ ID No:13” (para 22). The appellant submitted “that the antibody production process involved immunizing transgenic mice (HCo12) with two immunogens, both of which were artificially produced by modifying the human CD38 antigen” (para 7). The Court held that “The real challenge with regard to a patent application in respect of a synthesized non-living substance, especially a monoclonal antibody, is establishing novelty or technical advance and not patent eligibility.” (para 21)

5On inventive step, the Court in Genmab said that “apart from stating that the organism of origin of the CDR sequences is natural, the respondent also concluded that no comparative data was provided” and held, “On perusal of the complete specification, the affidavits discussed above and the cited prior arts, I find that there is no basis to the conclusion that the claimed invention either lacks technical advancement over the cited prior art or that it would have been obvious to a person skilled in the art.” (para 29) It held that “the objections on the basis of Section 3(c) and lack of inventive step are overruled” (para 31).

Provisions and topics

Provisions

Cases on this page

Case page

Immunas Pharma Inc v Assistant Controller of Patents and Designs (2024)

High Court of Madras·6 March 2024

Case page

Genmab A/S v Assistant Controller of Patents and Designs (2024)

High Court of Madras·6 March 2024

See also

Doctrine page

Discovery Is Not Invention

Can a discovery be patented in India?

Doctrine page

Patentability of Micro-organisms

Are micro-organisms patentable in India?

Doctrine page

Technical Advance

Against what knowledge is technical advance measured for inventive step in India?

Doctrine page · Written by Prof. Feroz Ali

www.aop.onl/antibody-claims